Impact of Paramedical Consultations in Oncological Supportive Care in Outpatients With Multiple Myeloma
NCT05355987 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20
Last updated 2026-01-02
Summary
Multiple myeloma is the second most frequent hematologic malignancy, which incidence augmented between 1995 and 2018, with an annual mean variation of +0.6% to 1.1%. Although treatment improved in the last years, the patients' prognostic is associated with cytogenetic abnormalities.
Oncological supportive care provides patients with a global perspective, in addition to specific medical treatment adapted to pathology and patient profile. It contributes to the improvement of quality of life of patients, throughout their care pathway regarding physical, psychological and social aspects, according to their specific needs as well as their caregivers'.
The aim of this study is to evaluate the quality of life at 6 months after multiple myeloma diagnosis in outpatients receiving paramedical consultations in oncological supportive care from the diagnosis versus outpatients receiving paramedical consultations in oncological supportive care after 6 months after diagnosis.
Conditions
Interventions
- OTHER
-
Early oncological supportive care
Several appointments (at diagnosis, 3 months, 6 months and 9 months) with nursing coordinator to define the needs in oncological supportive care. Different appointments will be planned according to patient's needs, with several possibilities: oncological supportive care nurse, social worker, psychologist, physiotherapist, adapted physical activity, medication reconciliation, oncologic geriatric medicine, dietician, nutritionist, smoking cessation advisor, sexologist, sophrologist, pain management nursing and palliative care, socio-aesthetician and religious cult coordinator.
- OTHER
-
Delayed oncological supportive care
Two appointments (6 months and 9 months) with nursing coordinator to define the needs in oncological supportive care. Different appointments will be planned according to patient's needs, with several possibilities: oncological supportive care nurse, social worker, psychologist, physiotherapist, adapted physical activity, medication reconciliation, oncologic geriatric medicine, dietician, nutritionist, smoking cessation advisor, sexologist, sophrologist, pain management nursing and palliative care, socio-aesthetician and religious cult coordinator.
Sponsors & Collaborators
-
Centre Henri Becquerel
lead OTHER
Principal Investigators
-
Amel Benchemam · Centre Henri Becquerel
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-06-03
- Primary Completion
- 2025-06-02
- Completion
- 2025-06-26
Countries
- France
Study Locations
More Related Trials
-
An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients
NCT03606577 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With Multiple Myeloma
NCT02197221 ·Status: COMPLETED ·Phase: PHASE3
-
Phase 1-2 Study of Total Bone Marrow Irradiation With Helicoidal Tomotherapy in 1st Myeloma Relapse
NCT01794572 ·Status: TERMINATED ·Phase: NA
-
Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma
NCT00367185 ·Status: COMPLETED ·Phase: PHASE3
-
Helical Tomotherapy in Multiple Myeloma
NCT05970198 ·Status: RECRUITING ·Phase: NA
-
Myeloma Treatment in Real Life
NCT03638232 ·Status: COMPLETED
-
Follow-up of Patients With Multiple Myeloma in the West-Occitanie Region "Living With a Myeloma in West-Occitanie"
NCT04888039 ·Status: RECRUITING
-
The Optimal Timing of a Second Autologous Peripheral Blood Stem Cell Transplantation in Patients (<61 Years) With Multiple Myeloma
NCT00207805 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT05160584 ·Status: RECRUITING
-
Factors Associated With Health-related Quality of Life and Social Participation of Patients With Multiple Myeloma and Their Caregivers
NCT07014865 ·Status: RECRUITING
-
A "Physician & Patient-powered" Cohort Registry (MY MYELOMA)
NCT05001087 ·Status: RECRUITING
-
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
NCT01241396 ·Status: COMPLETED
-
A Study of Real Life Treatment for Multiple Myeloma (MM)
NCT04985643 ·Status: ACTIVE_NOT_RECRUITING
-
Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma
NCT00995059 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Geriatric-assessment Interventions to Address Functional Deficits in Older Adults w Multiple Myeloma
NCT04999085 ·Status: COMPLETED ·Phase: NA
-
PASCA-MM Study. Impact of the PASCA (PArcours de Santé au Cours du CAncer) Program on Complications Associated With Multiple Myeloma and/or Its Treatments in the Context of a First Hematopoietic Stem Cell Autograft, in Adults Aged 18 to 70.
NCT05947136 ·Status: RECRUITING ·Phase: NA
-
An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants
NCT02761187 ·Status: TERMINATED
-
Quantitative and Qualitative Monocytes Analysis and Their Impact on CART Cells Reponse in Multiple Myeloma
NCT07180992 ·Status: RECRUITING
-
Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies
NCT02997813 ·Status: COMPLETED
-
Cost-utility Analysis of Ambulatory Dose Escalation of Bispecific Antibodies in Multiple Myeloma.
NCT06846905 ·Status: RECRUITING
-
MRI in Multiple Myeloma: Analysis of the Axial Skeleton Versus Whole Body. What is the Required Analysis?
NCT03618212 ·Status: TERMINATED
-
Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma
NCT00065351 ·Status: COMPLETED ·Phase: PHASE2
-
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
NCT00153933 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
NCT05050097 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Total Marrow Irradiation and High-dose Melphalan for Double Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
NCT01665014 ·Status: UNKNOWN ·Phase: PHASE2